4D Molecular Therapeutics (FDMT) executive compensation, 2026 proxy

David Kirn, M.D., President and Chief Executive Officer, was paid $2.1M in 2025, up 103% from $1M the year before.

Filed
April 28, 2026
Annual meeting
June 17, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.1M+103% vs prior year
CEO Target Bonus
60%Percentage of base salary
Corporate Achievement
140%For annual performance bonus
CFO Sign-on Bonus
$100,000Payable in two installments

How M.D. was paid

$2.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary33%Option awards40%Non-equity incentive27%All other compensation0%

Named executive officers

ExecutiveTotal
David Kirn, M.D.President and Chief Executive Officer$2,051,343
Kristian HumerChief Financial Officer$3,990,903
Fariborz Kamal, Ph.D.Former Chief Operating Officer & President$1,441,573

What changed and why

  • $2.1MCEO David Kirn received total compensation of $2,051,343 in 2025 compared to $1,009,004 in 2024.
  • 140%Corporate performance was achieved at 140% for the 2025 fiscal year.
  • $3.9MKristian Humer joined as Chief Financial Officer in November 2025 with an option award of $3,874,656.
  • $667KDr. Kirn's base salary increased to $667,252 for 2025.
  • $823KDr. Kirn received an option award valued at $822,750.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.